Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b73f8bd36fe7a3e9867f3ced99db2190 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
filingDate |
2016-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2021-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0264866b50c9dbab0c68a5242778898 |
publicationDate |
2021-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
RU-2743206-C2 |
titleOfInvention |
Double neurokinin-1/neurokinin-3 receptor antagonists for treating sex hormone dependent diseases |
abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to using a compound of double NK-1/NK-3 receptor antagonists of formula A or its pharmaceutically acceptable salt for preparing a drug for treating vasomotor symptoms.EFFECT: double neurokinin-1/neurokinin-3 receptor antagonists are proposed for treating sex hormone-dependent diseases.7 cl, 2 tbl, 1 ex |
priorityDate |
2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |